Since the program’s authorization in May 2025, between prior repurchases and the ASR, ADMA will have repurchased approximately $160 million of its common stock to date. Management believes these ...

(Nasdaq: ADMA) ("ADMA" or the "Company"), a U.S. based, end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing and developing specialty biologics, today announced its ...

RAMSEY, N.J. (AP) — RAMSEY, N.J. (AP) — Adma Biologics Inc. (ADMA) on Wednesday reported fourth-quarter earnings of $49.4 million. On a per-share basis, the Ramsey, New Jersey-based company said it ...

ADMA Biologics is a U.S.-based, end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing and developing specialty biologics for the treatment of immunodeficient patients ...

RAMSEY, N.J. and BOCA RATON, Fla., April 07, 2025 (GLOBE NEWSWIRE) -- ADMA Biologics, Inc. (ADMA) (“ADMA” or the “Company”), an end-to-end commercial biopharmaceutical company dedicated to ...

3Q 2025 Total Revenue of $134.2 Million, a 12% YoY Increase 3Q 2025 GAAP Net Income of $36.4 Million, a 1% YoY Increase 3Q 2025 Adjusted EBITDA (1) of $58.7 Million, a 29% YoY Increase 3Q 2025 ...

We recently compiled a list of the 12 Best Multibagger Stocks to Buy Right Now. In this article, we are going to take a look at where ADMA Biologics, Inc. (NASDAQ:ADMA) stands against the other ...